CTOs on the Move

Porzio Life Sciences

www.porziolifesciences.com

 
Regulatory compliance software solutions, products and services assist pharmaceutical, medical device and biotechnology companies in complying with marketing and sales regulations.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Womens International Pharmacy

It is the goal of Women's International Pharmacy, Inc. to provide excellent service and quality compounded prescriptions to our customers. At Women's International Pharmacy, Inc., we are dedicated to providing custom compounded doses of bioidentical

Bridge Laboratories

Bridge Laboratories is a Gaithersburg, MD-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Psych Hub

Psych Hub is the worlds largest online platform for mental health education. We train mental health providers, employers, organizations, and individuals on mental health.

Phathom Pharmaceuticals

Phathom Pharmaceuticals, launched in 2019 by Frazier Healthcare Partners and Takeda Pharmaceuticals, is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal (GI) diseases and disorders. The company is advancing the investigational agent vonoprazan, a novel potassium-competitive acid blocker (P-CAB). Vonoprazan has the potential to address multiple unmet needs among patients with gastroesophageal reflux disease (GERD) and other acid-related disorders.

Ascentage Pharma

Ascentage Pharma is a globally-focused, clinical-stage biopharmaceutical company developing novel small molecule therapies for cancers, hepatitis B and age-related diseases. Based on breakthrough technology from the University of Michigan, the Company`s expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death, in cancers. Ascentage has built a rich pipeline of six clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.